The Federal Trade Commission (FTC) today announced that it is officially suing major pharmacy benefit managers (PBMs) Express Scripts, Caremark, Optum, and their affiliated group purchasing organizations (GPOs), alleging that the corporations engaged in unfair rebating practices that have inflated the prices of insulin drugs and hindered the ability of patients to access them.1
The suit is months in the making; in July, the FTC released an interim report that recognized the outsized impact PBMs have as middlemen in the pharmaceutical industry, significantly affecting patient accessibility and affordability of critical prescription drugs.2
Shortly after the release of that interim report, multiple sources reported that the FTC was preparing to sue the previously mentioned PBMs, which are the 3 largest in the country, for their alleged unfair business practices. Now, the agency is officially bringing legal action against the corporations.3
“Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,” Rahul Rao, deputy director of the FTC’s Bureau of Competition, said in the news release.1 “The FTC’s administrative action seeks to put an end to the Big Three PBMs’ exploitative conduct and marks an important step in fixing a broken system.”
Specifically, the FTC is alleging that those 3 PBMs “created a perverse drug rebate system” that led to high rebates from drug manufacturers, inflating insulin prices in the process. Even when lower list prices would become available—potentially making the drug even more affordable for vulnerable patients—the PBMs “systematically excluded them in favor of high list price, highly rebated” insulin.1